Published in Hepatol Res on July 18, 2014
Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence. Int J Mol Sci (2015) 0.76
Contradictory immune response in post liver transplantation hepatitis B and C. Int J Inflam (2014) 0.76
High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation. World J Gastroenterol (2016) 0.75
Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin. Transplantation (2015) 0.75
Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med (1993) 4.43
The liver as a lymphoid organ. Annu Rev Immunol (2009) 4.03
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology (2009) 4.00
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol (2005) 2.19
Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis. Liver Transpl (2013) 2.15
Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination. Gastroenterology (2012) 1.97
Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology (2012) 1.94
Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology (2011) 1.89
Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet (1996) 1.78
Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol (2011) 1.74
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001. MMWR Surveill Summ (2003) 1.70
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl (2005) 1.68
Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors. Liver Transpl (2007) 1.58
Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transpl (2005) 1.52
Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology (2007) 1.49
Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology (1998) 1.48
A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl (2001) 1.47
Familial HBsAg-positive hepatoma: treatment with orthotopic liver transplantation and specific immunoglobulin. Br Med J (1978) 1.46
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology (2014) 1.43
A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology (2008) 1.27
Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol (2001) 1.20
Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol (2002) 1.18
Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology (1999) 1.17
Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol (2003) 1.08
Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant (2010) 1.05
Managing HBV in patients with impaired immunity. Gut (2010) 1.02
Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. J Clin Virol (2013) 0.99
Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis (2012) 0.98
Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl (2013) 0.97
Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl (2007) 0.96
Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant (2003) 0.95
Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology (2000) 0.94
Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. Liver Int (2012) 0.92
Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation. Hepatol Res (2012) 0.92
Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells. Hepatology (2010) 0.92
Evolving strategies to prevent HBV recurrence. Liver Transpl (2004) 0.91
Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine (2005) 0.90
Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin. J Gastroenterol (2013) 0.90
Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Transpl Int (2006) 0.90
Adoptive immune transfer of hepatitis B virus specific immunity from immunized living liver donors to liver recipients. Transplantation (2009) 0.89
Vaccination against hepatitis B in liver transplant recipients: pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells. Liver Transpl (2007) 0.88
In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology (2008) 0.88
Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl (2004) 0.88
Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. Drug Des Devel Ther (2013) 0.87
Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg (1999) 0.87
Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. Hepatol Int (2011) 0.87
Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation. J Gastroenterol Hepatol (2013) 0.87
Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation? J Gastroenterol (2013) 0.86
Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation (2004) 0.86
Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation (2007) 0.86
De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation. Antivir Ther (2011) 0.86
Successful hepatitis B vaccination in liver transplant recipients with donor-specific hyporesponsiveness. Transpl Int (2009) 0.84
Clinical study on prevention of HBV re-infection by entecavir after liver transplantation. Clin Transplant (2011) 0.83
Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl (2013) 0.83
One-year vaccination against hepatitis B virus with a MPL-vaccine in liver transplant patients for HBV-related cirrhosis. Transpl Int (2010) 0.82
Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg (1999) 0.82
Clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients. J Gastroenterol Hepatol (2014) 0.82
HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients. Dig Dis Sci (2010) 0.81
Clinical management of hepatitis B virus infection correlated with liver transplantation. Hepatobiliary Pancreat Dis Int (2010) 0.80
HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence. J Viral Hepat (2005) 0.80
Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts. J Gastroenterol (2010) 0.80
Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl (2001) 0.79
Double-dose double-phase use of second generation hepatitis B virus vaccine in patients after living donor liver transplantation: Not an effective measure in transplant recipients. Hepatol Res (2008) 0.79
Extended double-dosage HBV vaccination after liver transplantation is ineffective, in the absence of lamivudine and prior wash-out of human Hepatitis B immunoglobulins. Dig Liver Dis (2006) 0.78
Immunogenicity of different hepatitis B virus vaccination schedules in liver transplant recipients. Hepatol Res (2012) 0.77
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology (2014) 2.83
Detectability of colorectal neoplasia with fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT). J Gastroenterol (2011) 2.07
The presence of large serrated polyps increases risk for colorectal cancer. Gastroenterology (2010) 1.73
Intramuscular transplantation of engineered hepatic tissue constructs corrects acute and chronic liver failure in mice. J Hepatol (2009) 1.64
A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. J Gastroenterol Hepatol (2007) 1.54
Risk factors associated with local recurrence of early gastric cancers after endoscopic submucosal dissection. Gastrointest Endosc (2008) 1.52
Combination of sigmoidoscopy and a fecal immunochemical test to detect proximal colon neoplasia. Clin Gastroenterol Hepatol (2009) 1.51
Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid. J Gastroenterol Hepatol (2011) 1.49
Are bile duct lesions of primary biliary cirrhosis distinguishable from those of autoimmune hepatitis and chronic viral hepatitis? Interobserver histological agreement on trimmed bile ducts. J Gastroenterol (2005) 1.48
Mechanism of impaired regeneration of fatty liver in mouse partial hepatectomy model. J Gastroenterol Hepatol (2007) 1.46
Serum levels of platelet-derived growth factor-BB and vascular endothelial growth factor as prognostic factors for patients with fulminant hepatic failure. J Gastroenterol Hepatol (2011) 1.45
Twist expression promotes migration and invasion in hepatocellular carcinoma. BMC Cancer (2009) 1.44
Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci (2011) 1.44
Research on potential radiation risks in areas with nuclear power plants in Japan: leukaemia and malignant lymphoma mortality between 1972 and 1997 in 100 selected municipalities. J Radiol Prot (2004) 1.44
Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet (2012) 1.32
The outcome of living donor liver transplantation with prior spontaneous large portasystemic shunts. Transpl Int (2007) 1.32
Narrow-band imaging provides reliable screening for esophageal malignancy in patients with head and neck cancers. Am J Gastroenterol (2009) 1.30
Human hepatocyte carcinogenesis (review). Int J Oncol (2013) 1.28
Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci (2013) 1.25
Diagnostic accuracy of narrow-band imaging and pit pattern analysis significantly improved for less-experienced endoscopists after an expanded training program. Gastrointest Endosc (2010) 1.21
Stromal cell-derived factor-1 from biliary epithelial cells recruits CXCR4-positive cells: implications for inflammatory liver diseases. Lab Invest (2003) 1.13
Novel chromoendoscopic method using an acetic acid-indigocarmine mixture for diagnostic accuracy in delineating the margin of early gastric cancers. Dig Endosc (2009) 1.13
Effects of prophylactic splenic artery modulation on portal overperfusion and liver regeneration in small-for-size graft. Transplantation (2008) 1.12
Clinical characteristics and treatment outcomes of nineteen Japanese patients with gastrointestinal bezoars. Intern Med (2014) 1.11
Virulent strain of hepatitis E virus genotype 3, Japan. Emerg Infect Dis (2009) 1.11
The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol (2010) 1.11
Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. J Gastroenterol Hepatol (2011) 1.10
An essential role for the N-terminal fragment of Toll-like receptor 9 in DNA sensing. Nat Commun (2013) 1.09
Combined duodenal stent placement and endoscopic ultrasonography-guided biliary drainage for malignant duodenal obstruction with biliary stricture. Dig Endosc (2010) 1.08
Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update. Hepatol Res (2012) 1.07
Preoperative proximal splenic artery embolization: a safe and efficacious portal decompression technique that improves the outcome of live donor liver transplantation. Transpl Int (2007) 1.06
DNA methylation of colon mucosa in ulcerative colitis patients: correlation with inflammatory status. Inflamm Bowel Dis (2011) 1.06
Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res (2003) 1.05
Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol (2011) 1.05
Usefulness and problems of endoscopic ultrasonography in prediction of the depth of tumor invasion in early gastric cancer. Acta Med Okayama (2011) 1.04
Sano's capillary pattern classification for narrow-band imaging of early colorectal lesions. Dig Endosc (2011) 1.02
Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence. Pancreas (2013) 1.01
Endoscopic submucosal dissection in the colorectum: present status and future prospects. Dig Endosc (2009) 1.01
Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. Hepatology (2012) 1.01
Submucosal injection solution for gastrointestinal tract endoscopic mucosal resection and endoscopic submucosal dissection. Drug Des Devel Ther (2009) 1.00
Prevention of biliary complication in radiofrequency ablation for hepatocellular carcinoma-Cooling effect by endoscopic nasobiliary drainage tube. Eur J Radiol (2008) 1.00
Association of virus infected-T cell in severe hepatitis caused by primary Epstein-Barr virus infection. J Clin Virol (2005) 0.98
Risk factors for acute renal injury in living donor liver transplantation: evaluation of the RIFLE criteria. Transpl Int (2013) 0.98
Proton pump inhibitor dose-related healing rate of artificial ulcers after endoscopic submucosal dissection: a prospective randomized controlled trial. Digestion (2011) 0.97
Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvement. World J Gastroenterol (2010) 0.97
Lugol-voiding lesions are an important risk factor for a second primary squamous cell carcinoma in patients with esosphageal cancer or head and neck cancer. Am J Gastroenterol (2011) 0.96
Helicobacter pylori eradication may induce de novo, but transient and mild, reflux esophagitis: Prospective endoscopic evaluation. J Gastroenterol Hepatol (2008) 0.96
Duodenal follicular lymphoma: comprehensive gene expression analysis with insights into pathogenesis. Cancer Sci (2014) 0.96
Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. Am J Gastroenterol (2003) 0.96
Caspase induction by IgA antimitochondrial antibody: IgA-mediated biliary injury in primary biliary cirrhosis. Hepatology (2004) 0.95
Carbon dioxide submucosal injection cushion: an innovative technique in endoscopic submucosal dissection. Dig Endosc (2010) 0.94
Methylation status of normal background mucosa is correlated with occurrence and development of neoplasia in the distal colon. Hum Pathol (2009) 0.94
Comprehensive investigation of areae gastricae pattern in gastric corpus using magnifying narrow band imaging endoscopy in patients with chronic atrophic fundic gastritis. Helicobacter (2012) 0.94
Association of new arterial stiffness parameter, the cardio-ankle vascular index, with left ventricular diastolic function. J Atheroscler Thromb (2008) 0.94
Primary biliary cirrhosis - Autoimmune hepatitis overlap syndrome: A rationale for corticosteroids use based on a nation-wide retrospective study in Japan. Hepatol Res (2011) 0.94
Advantages of using thin endoscope-assisted endoscopic submucosal dissection technique for large colorectal tumors. Dig Endosc (2010) 0.93
Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma. Int J Cancer (2012) 0.93
CO(2) insufflation for potentially difficult colonoscopies: efficacy when used by less experienced colonoscopists. World J Gastroenterol (2009) 0.93
Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol Res (2011) 0.93
Specific endoscopic features of ulcerative colitis complicated by cytomegalovirus infection. World J Gastroenterol (2010) 0.92
In vitro analysis of gastric phytobezoar dissolubility by coca-cola, coca-cola zero, cellulase, and papain. J Clin Gastroenterol (2014) 0.92
The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis. J Gastroenterol (2012) 0.91
Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy. Cancer Immunol Immunother (2012) 0.91
Restored expression of the tumor suppressor gene RUNX3 reduces cancer stem cells in hepatocellular carcinoma by suppressing Jagged1-Notch signaling. Oncol Rep (2011) 0.91
Impact of narrow-band imaging in screening colonoscopy. Dig Endosc (2010) 0.90
Age-related methylation in normal colon mucosa differs between the proximal and distal colon in patients who underwent colonoscopy. Clin Biochem (2008) 0.90
Hyaluronan receptors involved in cytokine induction in monocytes. Glycobiology (2008) 0.90
Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: a case control study. J Gastroenterol Hepatol (2012) 0.90
Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma. J Gastroenterol (2011) 0.90
Serum glycan markers for evaluation of disease activity and prediction of clinical course in patients with ulcerative colitis. PLoS One (2013) 0.89
Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. Am J Gastroenterol (2012) 0.89
Partial splenic embolization facilitates the adherence to peginterferon in chronic hepatitis C with thrombocytopenia. Intern Med (2011) 0.89
Hepatic differentiation of mouse iPS cells in vitro. Cell Transplant (2010) 0.89
Comprehensive mapping of HLA-A0201-restricted CD8 T-cell epitopes on PDC-E2 in primary biliary cirrhosis. Hepatology (2002) 0.89
Sepsis-associated liver injury: Incidence, classification and the clinical significance. Hepatol Res (2012) 0.89
Colorectal endoscopic submucosal dissection for elderly patients at least 80 years of age. Surg Endosc (2011) 0.89
Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroenterol Hepatol (2011) 0.89
Magnified endoscopic features of duodenal follicular lymphoma and other whitish lesions. Acta Med Okayama (2015) 0.89
Long-term outcomes of endoscopic management for biliary strictures after living donor liver transplantation with duct-to-duct reconstruction. Transpl Int (2009) 0.88
Seventeen-year effects of eradicating Helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer; a prospective cohort study. J Gastroenterol (2014) 0.88
Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol (2009) 0.88
Intraductal oncocytic papillary neoplasm of the pancreas with celiac artery compression syndrome and a jejunal artery aneurysm: report of a case. Surg Today (2005) 0.88
The genetic diversity of Helicobacter pylori virulence genes is not associated with gastric atrophy progression. Acta Med Okayama (2013) 0.87
Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer. J Gastroenterol (2013) 0.87
Magnifying endoscopy for intestinal follicular lymphoma is helpful for prompt diagnosis. Gut Liver (2013) 0.87
Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma. Liver Int (2010) 0.87
Clinical features of antinuclear antibodies-negative type 1 autoimmune hepatitis. Hepatol Res (2008) 0.87
Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. Hepatol Int (2011) 0.87
Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation? J Gastroenterol (2013) 0.86
Clinical significance of B cell-activating factor in autoimmune pancreatitis. Pancreas (2011) 0.86
Resection of metachronous lymph node metastases from hepatocellular carcinoma after hepatectomy: report of four cases. Acta Med Okayama (2012) 0.86
[Post-operative complications peculiar to lumboperitoneal shunt: possible consequences due to side leakage of CSF from around the inserted spinal tube into the lumbar epidural space]. No Shinkei Geka (2011) 0.86
Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation (2007) 0.86
Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis. BMC Cancer (2011) 0.86
Potential of adenovirus-mediated REIC/Dkk-3 gene therapy for use in the treatment of pancreatic cancer. J Gastroenterol Hepatol (2014) 0.86